Investor profile
New Science Ventures has backed 7 European tech companies across 10 funding rounds between 2009 and 2022, joining rounds totalling €291M. Most active in Healthtech and Cleantech. Data as of 7 Aug 2026.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Northsea Therapeutics | Netherlands | 1 | €71M |
| Novadip Biosciences | Belgium | 2 | €59M |
| Paragraf | UK | 1 | €54M |
| ISORG | France | 2 | €40M |
| BioVex | UK |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Northsea Therapeutics | Other | €71M | 2021-12 |
| Paragraf | Series B | €54M | 2022-03 |
| Novadip Biosciences | Series B | €40M | 2022-11 |
| BioVex |
| 1 |
| €32M |
| Cambridge Epigenetix | UK | 2 | €24M |
| Zeotap | Germany | 1 | €12M |
| Series D+ |
| €32M |
| 2009-03 |
| ISORG | Series B | €24M | 2018-09 |
| Cambridge Epigenetix | Series B | €19M | 2016-03 |
| Novadip Biosciences | Series B | €19M | 2021-11 |
| ISORG | Series C | €16M | 2021-07 |
| Zeotap | Series B | €12M | 2017-01 |
| Cambridge Epigenetix | Series A | €4.4M | 2014-10 |
